Novo Nordisk AS (NVO) reports strong financial performance with a 24% sales increase, driven by demand for diabetes and ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed ...

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

Novo Nordisk ( (NVO) ) has released its Q3 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Novo ...

Novo Nordisk (NVO) revealed mixed third quarter results, the pharmaceutical giant narrowing its full-year sales growth guidance while posting a 79% year-over-year sales increase for its landmark ...

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations ...

Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.

Novo Nordisk (NVO) posts Q3 sales for its weight loss drug Wegovy, contrasting rival Eli Lilly's (LLY) quarterly miss for its obesity drug, Zepbound. Read more here.

Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year ...